TriangleNCT01001377 · OUTCOME
Duration of Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
What was measured
Duration of response (DOR), calculated only for those participants with an objective response, is the time from first objective response to disease progression per the RECIST v1.1 or death. Participants not meeting criteria for progression or who died by the analysis data cutoff date were censored at their last evaluable disease assessment date.
Analysis population: Participants with an objective response
Groups in this outcome
Cetuximab
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
Panitumumab
Panitumumab 6 mg/kg IV every 14 days.
| Group | Source count |
|---|---|
| Cetuximab | 96 |
| Panitumumab | 107 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cetuximab | 5.4 | Not reported | 3.8 | 5.5 | Not reported |
| Panitumumab | 3.8 | Not reported | 3.7 | 4.8 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 3.8
- upper Limit
- 5.5
- value
- 5.4
- group Id
- OG001
- lower Limit
- 3.7
- upper Limit
- 4.8
- value
- 3.8
- denoms
- counts
- group Id
- OG000
- value
- 96
- group Id
- OG001
- value
- 107
- units
- Participants
- description
- Duration of response (DOR), calculated only for those participants with an objective response, is the time from first objective response to disease progression per the RECIST v1.1 or death. Participants not meeting criteria for progression or who died by the analysis data cutoff date were censored at their last evaluable disease assessment date.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.
- id
- OG000
- title
- Cetuximab
- description
- Panitumumab 6 mg/kg IV every 14 days.
- id
- OG001
- title
- Panitumumab
- param Type
- MEDIAN
- population Description
- Participants with an objective response
- reporting Status
- POSTED
- time Frame
- From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
- title
- Duration of Response
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice